An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients

Trial Profile

An 8-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study Of Pregabalin (300-600 Mg/Day) And Venlafaxine XR (75-225 Mg/Day) For The Acute Treatment Of DSM-IV Generalized Anxiety Disorder In Outpatients

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Pregabalin (Primary) ; Venlafaxine
  • Indications Generalised anxiety disorder
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Mar 2009 Results published in International Clinical Psychopharmacology.
    • 07 Dec 2007 Results have been presented at the 7th International Forum on Mood and Anxiety Disorders.
    • 29 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top